Ivonescimab Improves Survival in HARMONI-6 Trial
The Future of Lung Cancer Treatment: Is a ‘Keytruda Successor’ Finally Here? For over a decade, Merck’s Keytruda has stood as the undisputed titan of oncology. With over 44 FDA indications and annual sales exceeding $30 billion, it transformed lung cancer from a terminal diagnosis into a manageable condition for many. Now, the medical community … Read more
